Combination treatment before surgery for stage II-III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of radiation, immunotherapy, and chemotherapy given before surgery for stage II or III lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have stage II or III lung cancer that can be removed with surgery
- Have not had prior treatment for lung cancer
- Have good overall health and ability to perform daily tasks
- Your tumor must not have certain gene changes (EGFR or ALK)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a combination of radiation, an immunotherapy drug called tislelizumab, and chemotherapy given before surgery for non-small cell lung cancer that has not spread too far (stage II-III). The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests a combination of low-dose radiation, focused high-dose radiation (SBRT), chemotherapy, and an immunotherapy drug (tislelizumab) for people with stage IIA to IIIB non-small cell lung cancer that hasn't been treated yet. The goal is to see if this approach can help shrink tumors and improve outcomes before or instead of surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.